Table 2.
Chemotherapy regimens (n = 102).
| Chemotherapy | Group A (n = 50) | Group B (n = 52) |
|---|---|---|
| VDC/IE | 5 | 43 |
| VACD | 9 | |
| VDC | 8 | |
| VAC | 3 | |
| MAP | 3 | |
| MAP with RT followed by VDD alternating with VDC | 5 | |
| MAP, IE | 3 | |
| Unknown regimen | 4 | 2 |
| VAC alternating with VDD | 1 | |
| VC | 2 | |
| VDC, 5FU | 1 | |
| VDCD | 1 | |
| IE | 1 | |
| DI | 1 | |
| CCT | 1 | |
| MDCI | 1 | |
| DDI | 1 | |
| No chemotherapy administered | 6 | |
| No chemotherapy information | 1 |
VDC/IE: vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide; VACD: vincristine, actinomycin D, cyclophosphamide, doxorubicin; VDC: vincristine, doxorubicin, cyclophosphamide; VAC: vincristine, actinomycin D, cyclophosphamide; MAP: mitomycin, Adriamycin, cisplatin; VDD: vincristine, doxorubicin, dacarbazine; VDCD: vincristine, doxorubicin, cyclophosphamide, dacarbazine; DI: doxorubicin, ifosfamide; CCT: cyclophosphamide, carboplatin, thiotepa; MDCI: mitomycin, doxorubicin, cisplatin, ifosfamide; DDI: doxorubicin, dacarbazine, ifosfamide.